MJ Lim-Fat

Start of the Educational Day of #SNO2025 and WFNOS2025. Welcoming by @mjlimfat.bsky.social. Looking forward to an inspiring conference in Honolulu. @neuroonc.bsky.social @eanoassociation.bsky.social

@mjlimfat.bsky.social closes the educational day at #EANO2025 with remarks and guidance on Pregnancy and Fertility Preservation in patients with brain tumors. @eanoassociation.bsky.social

Such an honor to be part of this education day! Congrats to the Education committee on a successful start to #EANO2025!

Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas Gliomas classified as CNS WHO grade 3 and 4 (herein referred to as HGG) are aggressive, fast-growing tumors with a poor prognosis and limited therapeutic o

Happy to share our collaborative Point/Counterpoint article on upfront #BRAF inhibition for adult high-grade #gliomas - a summary of the first joint SNO/EANO Young Investigators debate at #SNO2024. @marjoleingeurts.bsky.social @mjlimfat.bsky.social doi.org/10.1093/neuo...

🔗 www.soc-neuro-onc.org/SNO2025/SNO2...

Don’t miss this year’s @neuroonc.bsky.social SNO/WFNOS Education Day in Honolulu on Nov 20 2025- a unique program highlighting a 30 year global retrospective on clinical approaches in #neurooncology AND emerging technologies! 🌍🧬🔬
@eanoassociation.bsky.social #ASNO #SNOSSA #SNOLA

Truly to receive the Neuro-Oncology Investigator Award #AANAM2025. The AAN ‘s dynamic Neuro-Oncology Section is where I was first inspired to pursue Neuro-Oncology - a wonderful full circle moment among great friends, colleagues & mentors.

Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomas SUMMARY. The phase-3 INDIGO trial demonstrated that the IDH inhibitor vorasidenib significantly prolonged progression-free survival and delayed interventio

🚨 Study by Galldiks et al. showing metabolic response to vorasidenib in IDH-mut gliomas using PET monitoring. This highlights FET PET’s potential to provide earlier & more informative assessments of treatment response than MRI in patients receiving IDH-inhibitors
academic.oup.com/noa/advance-...

That’s a wrap on #SNO2024 in Houston! ✨ The #EANO team had an amazing time sharing knowledge, meeting outstanding colleagues and friends, and being part of such an inspiring event. Thank you, @neuroonc.bsky.social, for hosting this great conference!

#neurooncology #braintumor #cancer #btsm

What a great Victor Levin Award talk @neuroonc.bsky.social by @martinvandenbent.bsky.social, where he not only educated us on how to treat ow-grade glioma, but also inspired us to stay curious, persistent, and a little brave. A truly great mentor #sno2024

First joint SNO-EANO young investigators debate on clinical controversies. Thanks to all the amazing speaker and the audience! #SNO2024
@neuroonc.bsky.social
@eanoassociation.bsky.social

Mark your calendars 🗓️ Start your Friday at #SNO2024 with an active joint SNO/EANO debate on clinical controversies, feat. Derek Tsang and Felix Ehret on #protons vs. #photons. 👉🏼 7:15 ⏰ @eanoassociation.bsky.social

Learning already a lot about targeted therapy at the #SNO2024 educational day. Join the morning session tomorrow (7:15 ⏰) on upfront BRAF-inhibition in a joint SNO/EANO young investigators debate featuring M. Geurts and S. Perreault. #glioma #braintumor
@eanoassociation.bsky.social

To re-resect or not to re-resect, that is the question of the debate of Jacob Young and Philipp Karschnia tomorrow in the new young investigators joint debate @neuroonc.bsky.social @eanoassociation.bsky.social #SNO2024 #neurosurgery

Neurooncology Starter Pack Join the conversation

go.bsky.app/7f4adow

Great to see @neuroonc.bsky.social on 🦋 looking forward to a great meeting #SNO2024

Great presentations and discussions on serial biopsies and biologically driven designs at the #SNO2024 Biospecimen Workshop @roelverhaak.bsky.social